We sincerely thank the trial participants and their parents/guardians who agreed to take part in the trial, the data monitoring committee, the Dengue Case Adjudication Committee members, the Takeda expanded study team, the study team at PPD, and all the trial staff in each of the countries. We also acknowledge the contribution of the late Dan Stinchcomb and Inviragen, Inc. (Fort Collins, CO), in the initial developmental work of TAK-003 (Inviragen, Inc., was subsequently acquired by Takeda). We are grateful to Jenny Engelmoer (Sula Communications, Utrecht, Netherlands) and Miranda Dixon (Excel Medical Affairs, Horsham, West Sussex, UK) for editorial assistance in the preparation of this manuscript. The authors confirm that all ongoing and related trials for this drug/intervention are registered (#NCT02747927). This trial is registered at ClinicalTrials.gov (#NCT02747927, https://clinicaltrials.gov/ct2/show/NCT02747927).
Brady OJ , Gething PW , Bhatt S , Messina JP , Brownstein JS , Hoen AG , Moyes CL , Farlow AW , Scott TW , Hay SI , 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6: e1760.
Snow GE , Haaland B , Ooi EE , Gubler DJ , 2014. Review article: research on dengue during World War II revisited. Am J Trop Med Hyg 91: 1203–1217.
Montoya M , Gresh L , Mercado JC , Williams KL , Vargas MJ , Gutierrez G , Kuan G , Gordon A , Balmaseda A , Harris E , 2013. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 7: e2357.
- Search Google Scholar
- Export Citation
Montoya M Gresh L Mercado JC Williams KL Vargas MJ Gutierrez G Kuan G Gordon A Balmaseda A Harris E 2013. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 7: e2357.
Aguas R , Dorigatti I , Coudeville L , Luxemburger C , Ferguson NM , 2019. Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam. Sci Rep 9: 9395.
Bhoomiboonchoo P et al., 2015. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994–2010. BMC Public Health 15: 250.
Soo KM , Khalid B , Ching SM , Chee HY , 2016. Meta-analysis of dengue severity during infection by different dengue virus serotypes in primary and secondary infections. PLoS One 11: e0154760.
Biswal S et al., 2020. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet 395: 1423–1433.
Biswal S et al., 2019. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381: 2009–2019.
López-Medina E et al., 2022. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J Infect Dis 225: 1521–1532.
Rivera L et al., 2022. Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis 75: 107–117.
World Health Organization , 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control, 2nd edition .Geneva, Switzerland: WHO.
Forshey BM , Stoddard ST , Morrison AC , 2016. Dengue viruses and lifelong immunity: reevaluating the conventional wisdom. J Infect Dis 214: 979–981.